

Bernd Meibohm, Fcp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9059309/bernd-meibohm-fcp-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

6,146
citations

39
h-index

75
g-index

177
ext. papers

6,998
ext. citations

5.4
avg, IF

5.98
L-index

#	Paper	IF	Citations
158	Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 847021	5.6	0
157	Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and Study. <i>Journal of Chemical Information and Modeling</i> , 2021 , 61, 5469-5483	6.1	8
156	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1435-1448	6.2	3
155	Pediatric Dose Selection for Therapeutic Proteins. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S193-S206	2.9	2
154	Discovery of -(3,4-Dimethylphenyl)-4-(4-isobutylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 1930-1950	8.3	2
153	Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 881-888	2.9	3
152	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0174420	5.9	1
151	X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 13072-13095	8.3	1
150	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. <i>ACS Infectious Diseases</i> , 2021 , 7, 2850-2863	5.5	0
149	Time to Mind the Gap On novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2. <i>Current Opinion in Virology</i> , 2021 , 50, 1-7	7.5	3
148	Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. <i>Intensive Care Medicine</i> , 2020 , 46, 2284-2296	14.5	39
147	Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. <i>Clinical and Translational Science</i> , 2020 , 13, 219-223	4.9	8
146	Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. <i>Paediatric Drugs</i> , 2020 , 22, 199-216	4.2	20
145	Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 809-825	6.2	2
144	Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients. <i>Pharmaceutics</i> , 2020 , 12,	6.4	1
143	Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence. <i>ACS Applied Materials & Interfaces</i> , 2019 , 11, 38537-38554	9.5	17
142	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. <i>Tuberculosis</i> , 2019 , 114, 119-122	2.6	6

141	Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. <i>Tuberculosis</i> , 2019 , 117, 52-55	2.6	1
140	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2128-2138 ¹²	5.1	138
139	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins 2019 , 105-137		3
138	Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology? 2019 , 187-208		
137	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 915-922	2.9	1
136	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. <i>Pharmaceutical Research</i> , 2019 , 36, 136	4.5	10
135	Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 127, 233-239	5.1	5
134	Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. <i>Journal of Colloid and Interface Science</i> , 2019 , 535, 133-148	9.3	67
133	Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey. <i>British Journal of Pharmacology</i> , 2018 , 175, 1054-1065	8.6	25
132	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. <i>Current Pharmacology Reports</i> , 2018 , 4, 285-291	5.5	6
131	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular. <i>Frontiers in Microbiology</i> , 2018 , 9, 1895	5.7	3
130	Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. <i>AAPS Journal</i> , 2017 , 19, 447-455	3.7	4
129	Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies. <i>Pharmaceutical Research</i> , 2017 , 34, 1925-1933	4.5	4
128	Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. <i>Clinical Drug Investigation</i> , 2017 , 37, 705-707	3.2	2
127	Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 943-946	2.9	5
126	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 947-955	2.9	3
125	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 2869-2878	8.3	13
124	Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. <i>PLoS ONE</i> , 2017 , 12, e0172628	3.7	12

123	Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. <i>Journal of Caffeine Research</i> , 2017 , 7, 95-102		9
122	Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2687-2694	3.8	10
121	Pharmacokinetics of Monoclonal Antibodies. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017 , 6, 576-588	4.5	309
120	Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. <i>ACS Infectious Diseases</i> , 2017 , 3, 72-88	5.5	25
119	Pattern Recognition in Pharmacokinetic Data Analysis. <i>AAPS Journal</i> , 2016 , 18, 47-63	3.7	13
118	Phase II Metabolic Pathways of Spectinamide Antitubercular Agents: A Comparative Study of the Reactivity of 4-Substituted Pyridines to Glutathione Conjugation. <i>MedChemComm</i> , 2016 , 7, 114-117	5	7
117	Translational PK/PD of anti-infective therapeutics. <i>Drug Discovery Today: Technologies</i> , 2016 , 21-22, 41-49	4.1	16
116	Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 916-23	4	9
115	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 999-1004	4	18
114	Urinary metabolites from mango (<i>Mangifera indica</i> L. cv. Keitt) galloyl derivatives and in vitro hydrolysis of gallotannins in physiological conditions. <i>Molecular Nutrition and Food Research</i> , 2016 , 60, 542-50	5.9	24
113	Drug Development of Therapeutic Monoclonal Antibodies. <i>BioDrugs</i> , 2016 , 30, 275-93	7.9	52
112	Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products. <i>Clinical Pharmacology in Drug Development</i> , 2016 , 5, 52-6	2.3	3
111	Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. <i>AAPS Journal</i> , 2016 , 18, 788-91	3.7	5
110	Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method. <i>PLoS ONE</i> , 2016 , 11, e0149225	3.7	21
109	From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. <i>Clinical and Experimental Immunology</i> , 2016 , 184, 137-46	6.2	51
108	Tools for predicting the PK/PD of therapeutic proteins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1115-25	5.5	18
107	Ethanol lock therapy: a pilot infusion study in infants. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 431-6	2.9	5
106	Clinical pharmacology of bispecific antibody constructs. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S21-8	2.9	29

105	Effects of alcohol on human carboxylesterase drug metabolism. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 627-68	25
104	ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds 2015 , 1-16	
103	In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. <i>Scientific Reports</i> , 2015 , 5, 13985	4.9 32
102	Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 266-87	6.1 123
101	Challenges and considerations for development of therapeutic proteins in pediatric patients. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S103-15	2.9 21
100	Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. <i>Science Translational Medicine</i> , 2015 , 7, 288ra75	17.5 14
99	Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. <i>Pharmacology Research and Perspectives</i> , 2015 , 3, e00159	3.1 25
98	Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. <i>Nature Medicine</i> , 2014 , 20, 152-158	50.5 132
97	Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution. <i>AAPS Journal</i> , 2014 , 16, 311-23	3.7 3
96	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologicals</i> , 2014 , 42, 177-83	1.8 120
95	Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. <i>PLoS ONE</i> , 2014 , 9, e87909	3.7 19
94	Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function. <i>PLoS ONE</i> , 2014 , 9, e100776	3.7 42
93	Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 863-4	6.2 4
92	Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2013 , 36, 236-40	1.4 35
91	Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 855-68	6.2 156
90	Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. <i>AAPS Journal</i> , 2013 , 15, 447-54	3.7 21
89	Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicability to pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 72, 245-50	3.5 15
88	Response to "Physiologically based pharmacokinetic modeling at the extremes of age". <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 149	6.1 4

87	Genetic variation in antioxidant enzymes, cigarette smoking, and longitudinal change in lung function. <i>Free Radical Biology and Medicine</i> , 2013 , 63, 304-12	7.8	14
86	Pharmacokinetics of intravenous amiodarone in children. <i>Archives of Disease in Childhood</i> , 2013 , 98, 989-93		12
85	Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 159-70	3.8	15
84	Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics 2013 , 101-132		8
83	Antitubercular nitrofurans isoxazolines with improved pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 6063-72	3.4	34
82	Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. <i>AAPS Journal</i> , 2012 , 14, 296-302	3.7	209
81	The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 516-26	7	66
80	Creatinine-based vancomycin dosing regimens in neonates: there is more to consider than the variation in drug assay. <i>Pharmacotherapy</i> , 2012 , 32, e174; discussion e175	5.8	5
79	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins 2012 , 337-367		4
78	Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. <i>Pharmacotherapy</i> , 2012 , 32, 408-19	5.8	34
77	Genetic variation in antioxidant enzymes and lung function. <i>Free Radical Biology and Medicine</i> , 2012 , 52, 1577-83	7.8	10
76	Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. <i>PLoS Genetics</i> , 2012 , 8, e1003098	6	108
75	Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 622-32	10.2	131
74	Characterizing the impact of renal impairment on the clinical pharmacology of biologics. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 54S-62S	2.9	91
73	Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study. <i>PLoS ONE</i> , 2012 , 7, e42065	3.7	12
72	Cognitive Impairment and Medication Complexity in Community-Living Older Adults: The Health, Aging and Body Composition Study. <i>Journal of Pharmacy Technology</i> , 2012 , 28, 156-162	0.6	5
71	Genetic ancestry-smoking interactions and lung function in African Americans: a cohort study. <i>PLoS ONE</i> , 2012 , 7, e39541	3.7	25
70	Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 823-4	6.2	3

69	Study design and simulation approach. <i>Handbook of Experimental Pharmacology</i> , 2011 , 205, 125-48	3.2	2
68	Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. <i>AAPS Journal</i> , 2011 , 13, 274-83	3.7	23
67	Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. <i>AAPS Journal</i> , 2011 , 13, 650-61	3.7	10
66	Pharmacokinetics of a combination of Δ -tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock. <i>Biopharmaceutics and Drug Disposition</i> , 2011 , 32, 89-98	1.7	2
65	Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?. <i>Thorax</i> , 2011 , 66, 961-9	7.3	68
64	Pharmacokinetics of ponazuril after oral administration to healthy llamas (<i>Lama glama</i>). <i>American Journal of Veterinary Research</i> , 2011 , 72, 1386-9	1.1	8
63	Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. <i>Nature Genetics</i> , 2011 , 43, 1082-90	36.3	313
62	Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 214-25	2.9	18
61	Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 9S-19S	2.9	15
60	The current role of model-based drug development. <i>Expert Opinion on Drug Discovery</i> , 2010 , 5, 311-21	6.2	23
59	Genetic ancestry in lung-function predictions. <i>New England Journal of Medicine</i> , 2010 , 363, 321-30	59.2	182
58	In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. <i>Future Medicinal Chemistry</i> , 2010 , 2, 1355-69	4.1	43
57	Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 7414-27	8.3	93
56	Population pharmacokinetics of therapeutic monoclonal antibodies. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 633-59	6.2	332
55	Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. <i>Annals of Epidemiology</i> , 2010 , 20, 223-32	6.4	25
54	A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. <i>Tuberculosis</i> , 2009 , 89, 378-85	2.6	24
53	The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 889-904	2.9	53
52	Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 511-22	3.8	46

51	Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 267-78	2.9	65
50	A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. <i>Clinica Chimica Acta</i> , 2008 , 398, 105-12	6.2	77
49	A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1037-45	5.1	75
48	Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. <i>Current Medicinal Chemistry</i> , 2008 , 15, 809-25	4.3	28
47	Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (<i>Euterpe oleracea</i> Mart.) in human healthy volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2008 , 56, 7796-802	5.7	175
46	Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. <i>AAPS Journal</i> , 2008 , 10, 157-65	3.7	29
45	Concepts and challenges in quantitative pharmacology and model-based drug development. <i>AAPS Journal</i> , 2008 , 10, 552-9	3.7	76
44	Discovery of novel isoxazolines as anti-tuberculosis agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 6638-42	2.9	69
43	Pharmacokinetics of Peptides and Proteins 2006 , 15-43		5
42	The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs 2006 , 1-13		3
41	Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs 2006 , 181-188		9
40	ExposureResponse Relationships for Therapeutic Biologic Products 2006 , 295-327		12
39	Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein 2006 , 373-393		6
38	Bioanalytical Methods Used for Pharmacokinetic Evaluations of Biotech Macromolecule Drugs: Issues, Assay Approaches, and Limitations 2006 , 145-180		1
37	Bioequivalence of Biologics 2006 , 189-208		1
36	Pharmacokinetics and Pharmacodynamics of Biotech Drugs 2006 ,		1
35	G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 373-9	2.9	45
34	Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 1172-81	4.7	24

33	Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1322-30	15.1	62
32	The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 987-1003	2.9	127
31	Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 1137-44	2.9	31
30	Pharmacokinetics and Pharmacodynamics of Biotech Drugs 2005 , 145-172		2
29	SYBR Green-based real-time PCR allelic discrimination assay for beta2-adrenergic receptor polymorphisms. <i>Analytical Biochemistry</i> , 2005 , 344, 292-4	3.1	8
28	Population pharmacokinetic studies in pediatrics: issues in design and analysis. <i>AAPS Journal</i> , 2005 , 7, E475-87	3.7	145
27	LC/MS/MS in drug development: targeting the brain. <i>BioTechniques</i> , 2005 , Suppl, 19-23	2.5	3
26	Pharmacokinetic aspects of biotechnology products. <i>Journal of Pharmaceutical Sciences</i> , 2004 , 93, 2184-204	3.0	222
25	Real-time PCR-based genotyping assay for CXCR2 polymorphisms. <i>Clinica Chimica Acta</i> , 2004 , 341, 93-106.	2	13
24	Pharmacokinetics of Protein- and Nucleotide-Based Drugs 2004 ,		2
23	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 555-564	2.9	109
22	The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 555-64	2.9	29
21	Pharmacokinetic/pharmacodynamic studies in drug product development. <i>Journal of Pharmaceutical Sciences</i> , 2002 , 91, 18-31	3.9	103
20	How important are gender differences in pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 329-42	6.2	297
19	Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. <i>AAPS PharmSci</i> , 2002 , 4, E29		16
18	Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. <i>American Heart Journal</i> , 2002 , 143, 916-22	4.9	105
17	Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. <i>Pharmaceutical Research</i> , 1999 , 16, 176-85	4.5	219
16	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999 , 27, 127-47		15

15	Dependency of cortisol suppression on the administration time of inhaled corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 704-10	2.9	26
14	Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 893-903	2.9	21
13	Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 938-41	2.9	47
12	Biopharmaceutical Challenges: Delivery of Oligonucleotides243-269		
11	Pharmacokinetics of Viral and Non-Viral Gene Delivery Vectors121-144		1
10	Monographs for Drug-Drug Interactions of Therapeutics Biologics1		
9	Drug Interactions for Therapeutic Proteins: A Journey Just Beginning1		
8	Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Protein Therapeutics1		1
7	Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs271-294		
6	Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent329-351		2
5	Clinical Drug Development of Cetuximab, a Monoclonal Antibody353-371		8
4	Pharmacokinetics of Monoclonal Antibodies45-91		28
3	Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides93-120		6
2	Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides209-242		1
1	Pharmacokinetics and Half-Life of Protein Therapeutics23-38		6